Objective： To evaluate the long-term clinical effect of Tangyiping Granules（糖异平颗粒, TYP） on patients with impaired glucose tolerance（IGT） to achieve normal glucose tolerance（NGT） and hence preventing them f...Objective： To evaluate the long-term clinical effect of Tangyiping Granules（糖异平颗粒, TYP） on patients with impaired glucose tolerance（IGT） to achieve normal glucose tolerance（NGT） and hence preventing them from conversion to diabetes mellitus（DM）. Methods： In total, 127 participants with IGT were randomly assigned to the control（63 cases, 3 lost to follow-up） and treatment groups（64 cases, 4 lost to follow-up） according to the random number table. The control group received lifestyle intervention alone, while the patients in the treatment group took orally 10 g of TYP twice daily in addition to lifestyle intervention for 12 weeks. The rates of patients achieving NGT or experiencing conversion to DM as main outcome measure were observed at 3, 12, and 24 months after TYP treatment. The secondary outcome measures included fasting plasma glucose（FPG）, 2-h postprandial plasma glucose（2h PG）, glycosylated hemoglobin（Hb A1c）, fasting insulin（FINS）, 2-h insulin（2hI NS）, homeostatic model assessment of insulin resistance（HOMA-IR）, blood lipid and patients＇ complains of Chinese medicine（CM） symptoms before and after treatment. Results： A higher proportion of the treatment group achieved NGT compared with the control group after 3-, 12- and 24-month follow-up（75.00% vs. 43.33%, 58.33% vs. 35.00%, 46.67% vs. 26.67%, respectively, P〈0.05）. The IGT to DM conversion rate of the treatment group was significantly lower than that of the control group at the end of 24-month follow-up（16.67% vs. 31.67%, P〈0.05）. Before treatment, FPG, 2h PG, Hb A1 c, FINS, 2h INS, HOMA-IR, triglyceride（TG）, total cholesterol, low- and high-density lipoprotein cholesterol levels had no statistical difference between the two groups（P〉0.05）. After treatment, the 2hP G, HbA 1c, HOMA-IR, and TG levels of the treatment group decreased significantly compared with those of the control group（P〈0.05）. CM symptoms such as exhaustion, irritability, chest tightness and breathless, spontaneous sweating, constipation, and dark thick and greasy tongue were significantly improved in the treatment group as compared with the control group（P〈0.05）. No severe adverse events occurred. Conclusion： TYP administered at the IGT stage with a disciplined lifestyle delayed IGT developing into type 2 DM.展开更多
目的基于Markov模型评价益气活血中药联合西医常规干预不稳定性心绞痛(unstable angina,UA)支架术后气虚血瘀证患者的远期疗效。方法根据益气活血中药联合西医常规干预、西医常规干预UA支架术后患者的预后和转归建立Markov模型。通过40...目的基于Markov模型评价益气活血中药联合西医常规干预不稳定性心绞痛(unstable angina,UA)支架术后气虚血瘀证患者的远期疗效。方法根据益气活血中药联合西医常规干预、西医常规干预UA支架术后患者的预后和转归建立Markov模型。通过40个Markov周期的状态转移概率和人均累积获得质量调整生命年(quality-adjusted life years,QALYs)的比较,评价益气活血中药联合西医常规干预的疗效优势。结果经过Markov模型20年的预测,益气活血中药联合西医常规干预组血运重建、非致命性心肌梗死、非致命性中风、全因死亡的累积转移概率分别为56.65%、6.53%、5.16%、31.66%,人均累积QALYs为12.95;西医常规干预组相应的累积转移概率分别为55.31%、6.87%、5.25%、32.57%,人均累积QALYs为12.84。与西医常规干预比较,益气活血中药联合西医常规干预的人均增量QALYs为0.11。结论基于Markov模型的预测结果,益气活血中药联合西医常规干预UA支架术后患者的疗效优于西医常规干预,说明益气活血中药可以改善UA支架术后气虚血瘀患者的远期疗效。展开更多
基金Supported by Shandong Province Science and Technology Program for Public Wellbing(No.2014kjhm0106)Shandong Province Science and Technology Development Plan(No.2006GG3202011),China
文摘Objective： To evaluate the long-term clinical effect of Tangyiping Granules（糖异平颗粒, TYP） on patients with impaired glucose tolerance（IGT） to achieve normal glucose tolerance（NGT） and hence preventing them from conversion to diabetes mellitus（DM）. Methods： In total, 127 participants with IGT were randomly assigned to the control（63 cases, 3 lost to follow-up） and treatment groups（64 cases, 4 lost to follow-up） according to the random number table. The control group received lifestyle intervention alone, while the patients in the treatment group took orally 10 g of TYP twice daily in addition to lifestyle intervention for 12 weeks. The rates of patients achieving NGT or experiencing conversion to DM as main outcome measure were observed at 3, 12, and 24 months after TYP treatment. The secondary outcome measures included fasting plasma glucose（FPG）, 2-h postprandial plasma glucose（2h PG）, glycosylated hemoglobin（Hb A1c）, fasting insulin（FINS）, 2-h insulin（2hI NS）, homeostatic model assessment of insulin resistance（HOMA-IR）, blood lipid and patients＇ complains of Chinese medicine（CM） symptoms before and after treatment. Results： A higher proportion of the treatment group achieved NGT compared with the control group after 3-, 12- and 24-month follow-up（75.00% vs. 43.33%, 58.33% vs. 35.00%, 46.67% vs. 26.67%, respectively, P〈0.05）. The IGT to DM conversion rate of the treatment group was significantly lower than that of the control group at the end of 24-month follow-up（16.67% vs. 31.67%, P〈0.05）. Before treatment, FPG, 2h PG, Hb A1 c, FINS, 2h INS, HOMA-IR, triglyceride（TG）, total cholesterol, low- and high-density lipoprotein cholesterol levels had no statistical difference between the two groups（P〉0.05）. After treatment, the 2hP G, HbA 1c, HOMA-IR, and TG levels of the treatment group decreased significantly compared with those of the control group（P〈0.05）. CM symptoms such as exhaustion, irritability, chest tightness and breathless, spontaneous sweating, constipation, and dark thick and greasy tongue were significantly improved in the treatment group as compared with the control group（P〈0.05）. No severe adverse events occurred. Conclusion： TYP administered at the IGT stage with a disciplined lifestyle delayed IGT developing into type 2 DM.
文摘目的基于Markov模型评价益气活血中药联合西医常规干预不稳定性心绞痛(unstable angina,UA)支架术后气虚血瘀证患者的远期疗效。方法根据益气活血中药联合西医常规干预、西医常规干预UA支架术后患者的预后和转归建立Markov模型。通过40个Markov周期的状态转移概率和人均累积获得质量调整生命年(quality-adjusted life years,QALYs)的比较,评价益气活血中药联合西医常规干预的疗效优势。结果经过Markov模型20年的预测,益气活血中药联合西医常规干预组血运重建、非致命性心肌梗死、非致命性中风、全因死亡的累积转移概率分别为56.65%、6.53%、5.16%、31.66%,人均累积QALYs为12.95;西医常规干预组相应的累积转移概率分别为55.31%、6.87%、5.25%、32.57%,人均累积QALYs为12.84。与西医常规干预比较,益气活血中药联合西医常规干预的人均增量QALYs为0.11。结论基于Markov模型的预测结果,益气活血中药联合西医常规干预UA支架术后患者的疗效优于西医常规干预,说明益气活血中药可以改善UA支架术后气虚血瘀患者的远期疗效。
